Actively Recruiting
Study of Autoimmune Endocrine Antibodies in Adults Starting Immune Checkpoint Therapy for Cancer
Led by Laura ICONARU · Updated on 2025-05-29
500
Participants Needed
3
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the use of immune checkpoint inhibitor therapy for cancer treatment, focusing on the immune systems role in attacking tumor cells. This therapy works by removing brakes from the immune system using antibodies, but it can also cause the immune system to attack the bodys own cells, leading to autoimmune side effects such as skin rashes, diarrhea, hepatitis, or hypothyroidism. The study aims to find biomarkers that predict these side effects and possibly indicate better cancer treatment outcomes by analyzing antibodies related to autoimmune endocrine diseases before starting immune therapy. The study involves collecting blood samples from participants before and during immune checkpoint therapy to measure levels of various autoimmune endocrine disease-related antibodies, including anti-thyroglobulin, anti-thyroperoxidase, TSH receptor, pituitary, adrenal, and anti-glutamic acid decarboxylase antibodies. These samples will help evaluate the link between these antibodies, the development of endocrine immune-related side effects, and the impact on tumor response, progression-free survival, and overall survival. Participants receiving standard immune checkpoint therapy at study sites will be included. Participants will be followed prospectively with blood tests at baseline, 3 months, and 6 months after starting therapy to monitor antibody levels. Researchers will assess the relationship between antibody presence and the development of endocrine side effects as well as cancer outcomes. The study includes regular clinical visits aligned with usual care, and participants data will contribute to understanding potential prognostic factors for life-threatening endocrine complications and tumor response during immune checkpoint therapy.
CONDITIONS
Brief Title
Autoimmune Endocrine Disease Related Antibodies Before the Start of Immune Checkpoint Inhibitor Therapy
Research Team
J
Jeroen de Filette, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here